Skip to content

Welcome to Discover Pharma! Today is : October 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Parkinson’s disease

  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Ariadne Bio launches with Parkinson’s apathy drug candidate

    Ariadne Bio has launched with funding from The Michael J [...]

    September 18, 2026
  • Central Nervous System,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Amyl Therapeutics raises €8.25M to advance pan-amyloid neurodegenerative disease platform

    Amyl Therapeutics has raised €8.25m to generate preclinical data for [...]

    September 14, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Remepy raises $36M to advance Parkinson’s drug into Phase 3

    Remepy has raised $36M in a Series A financing round [...]

    August 14, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AC Immune gets FDA Fast Track for Parkinson’s immunotherapy ACI-7104

    AC Immune has received FDA Fast Track designation and IND [...]

    August 12, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    BioVie reports Phase 2 Parkinson’s trial results for bezisterim

    BioVie has reported topline results from a Phase 2 trial [...]

    August 7, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AC Immune advances Parkinson’s and Alzheimer’s pipeline with key clinical milestones ahead

    AC Immune has outlined a series of clinical milestones expected [...]

    August 5, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug

    ABLi Therapeutics has reported coordinated changes across 11 biomarkers linked [...]

    August 4, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Research & Development

    Mission Therapeutics signs US$292M deal for acute kidney injury programme

    Mission Therapeutics has signed a deal worth up to US$292 [...]

    July 20, 2026
  • Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Research & Development

    Remepy study links Hybridopa brain changes to improved Parkinson’s outcomes

    Remepy has published new peer-reviewed findings showing that its investigational [...]

    July 2, 2026
  • Pharmaceuticals and therapeutics,Therapeutic Areas

    Scenic Biotech joins Michael J. Fox Foundation Parkinson’s research programme

    Scenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 [...]

    June 11, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • E2 secures FDA clearance for pulmonary embolism thrombectomy system
    Categories: Clinical & Regulatory, Medical devices
  • Carterra and AstraZeneca target AI-driven drug discovery
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Research & Development
  • Biopharma dealmaking outlook improves despite investor caution
    Categories: Biotech & Pharma Business, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top